Ministry of Health and Welfare Expedites Insurance Listing as Samjin Pharmaceutical Takes Over Production

New Epilepsy Drug Brivaracetam Also Reduces Patient Costs to 170,000 Won Per Year

The supply of Lorazepam injection, an essential drug used in pediatric and emergency medical settings, will continue stably within the national health insurance coverage system, overcoming concerns over a potential supply disruption.


'Avoiding the Ativan Shortage'... Samjin Lorazepam Injection to Be Covered by Health Insurance Starting in July View original image

On June 30, the Ministry of Health and Welfare announced that, starting July 1, health insurance benefits will be applied to "Samjin Lorazepam Injection" and epilepsy medication containing the active ingredient brivaracetam, as part of its efforts to ensure the stable supply of essential medicines and enhance patient coverage.


Samjin Lorazepam Injection (formerly known as Ativan) is an injectable formulation of lorazepam used to alleviate acute anxiety and tension. It is a key essential medicine employed in emergency rooms and pediatric care settings for seizure control and sedation therapy. However, since last year, the domestic supply from the previous manufacturer became unstable, raising concerns about supply interruptions.


In response, the Ministry of Health and Welfare and the Ministry of Food and Drug Safety discussed measures to ensure a stable supply. Ultimately, Samjin Pharm was chosen to take over the production and supply of this medicine. The Ministry of Food and Drug Safety completed the approval process for the change of manufacturer, and the Ministry of Health and Welfare expedited the process for listing the changed product under the national health insurance, ensuring that it will be supplied to medical sites without delay from July 1.


A new medication for epilepsy has also been included in the insurance coverage to reduce the financial burden on patients. Starting July 1, health insurance will cover a total of 29 products containing the active ingredient brivaracetam, which reduces neurological side effects compared to existing drugs. As a result, patients aged 16 and older with epilepsy will have more options for partial seizure treatment, and the annual out-of-pocket medical expenses per patient are expected to decrease from approximately 560,000 won to 170,000 won.



Kwon Byeonggi, Director of the Health Insurance Policy Bureau at the Ministry of Health and Welfare, stated, "We hope this expansion of insurance coverage will ease the financial burden on patients and their families. In addition, just as we supported the rapid listing of Samjin Lorazepam Injection, we will continue efforts to address supply anxieties in the medical field and ensure that essential medicines needed by the public are stably supplied."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing